SavedAdd your journal

Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2016 / Cilt: 25 - Sayı: 1

Varicella Zoster Infection Under Valganciclovir Prophylaxis After Renal Transplantation

Böbrek Nakli Sonrası Valgansiklovir Profilaksisi Altında Gelişen Varisella Zoster Enfeksiyonu

Ahmet KIYKIM
Simge BARDAK
Kenan TURGUTALP
Mahmut Bakır KOYUNCU
Gülden ERSÖZ
Pages
104–106
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We describe a patient who did not have a VZV infection history in childhood and suffered from disseminated VZV infection with skin, liver and left eye involvement 5½ months after renal transplantation under valgancyclovir prophilaxis for CMV, and discuss the management of primary VZV infection

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Intensive immunosuppressive therapy in renal transplant patients increases the risk for infectious diseases.
📊
Key Findings & Data:Mortality rate due to disseminated VZV infection is as high as 30%.
💡
Conclusion & Impact:We describe a patient who did not have a VZV infection history in childhood and suffered from disseminated VZV infection with skin, liver and left eye involvement 5½ months after renal transplantation under valgancyclovir prophilaxis for CMV, and discuss the management of primary VZV infection
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Intensive immunosuppressive therapy in renal transplant patients increases the risk for infectious diseases. Varicella zoster virus (VZV) infection is one of these infectious diseases and can occur either primarily or with reactivation of latent disease with disseminated skin lesions or visceral involvement. Mortality rate due to disseminated VZV infection is as high as 30%. Valacyclovir and valganciclovir, which are wide spectrum antiherpetic agents used for cytomegalovirus (CMV) prophylaxis, act against not only CMV but also herpes simplex virus (HSV) and VZV. We describe a patient who did not have a VZV infection history in childhood and suffered from disseminated VZV infection with skin, liver and left eye involvement 5½ months after renal transplantation under valgancyclovir prophilaxis for CMV, and discuss the management of primary VZV infection

Özet

Böbrek nakilli hastalara uygulanan yoğun immünsüpresif tedavi bir çok enfeksiyon hastalığı riskinde artışa neden olmaktadır. Bu enfeksiyonlar arasında yer alan varisella virüs enfeksiyonu (VZV) primer veya reaktivasyona ikincil olarak yaygın deri tutulumu veya spesifik doku ya da organ tutulumu ile seyredebilmektedir. Yaygın VZV enfeksiyonuna bağlı mortalite %30'a varabilmektedir. Sitomegalovirüs (CMV) profilaksisi amacıyla kullanılabilen ve geniş spektrumlu antiherpetik bir ajan olan valasiklovir ve valgansiklovir CMV'ye ek olarak herpes simpleks virüs (HSV), VZV gibi diğer herpesvirüs enfeksiyonlarına karşı da koruyucu olduğu düşünülmektedir. Burada, çocukluk çağında VZV enfeksiyonu geçirmemiş olan ve böbrek naklinden 5½ ay sonra, valgansiklovir profilaksisi altında gelişen ve yaygın deri, karaciğer ve sol göz tutulumu gösteren VZV enfeksiyonlu hasta ve yönetimi sunulmuştur

🔖

Cite This Article

KIYKIM, A., BARDAK, S., TURGUTALP, K., KOYUNCU, M. B., ERSÖZ, G. (2022). Varicella Zoster Infection Under Valganciclovir Prophylaxis After Renal Transplantation. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 25 - Sayı: 1, 104–106. https://ajindex.com/articles/636152

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Floege J, Johnson RJ, Feehally J: Comprehensive Clinical Nephrology (4th ed). Philadelphia: Elsevier Saunders, 2010;1177- 1188 Rommelaere M, Maréchal C, Yombi JC, Goffin E, Kanaan N: Disseminated varicella zoster virus infection in adult renal transplant recipients: Outcome and risk factors. Transplant Proc 2012;44:2814-2817
  2. Fiddian P, Sabin CA, Griffiths PD: Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J Infect Dis 2002;186: 110-115 Fishman JA: Infection in renal transplant recipients. Semin Nephrol 2007;27:445-461
  3. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK: Herpes zoster infection following solid organ transplantation: Incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004;4:108-115
  4. Miller GG, Dummer JS: Herpes simplex and varicella zoster viruses: Forgotten but not gone. Am J Transplant 2007;7:741-747
  5. Heininger U, Seward JF: Varicella. Lancet 2006;368:1365-1376
  6. Pergama SA, Limayeb AP; AST Infectious Diseases Community of Practice: Varicella Zoster Virus (VZV) in solid organ transplant recipients. Am J Transplant 2009;9:108-115
  7. Fehr T, Bossart W, Wahl C, Binswanger U: Disseminated varicella infection in adult renal allograft recipients: Four cases and a review of the literature. Transplantation 2002;73:608-611
  8. Mustapic Z, Basic-Jukic N, Kes P. Lovcic V, Bubic-Filipi Lj, Mokos I, Kastelan Z, Zekan S: Varicella Zoster Infection in renal transplant recipients: Prevalence, complications and outcome. Kidney Blood Press Res 2011;34:382-386
  9. Squifflet JP, Legendre C: The economic value of valacyclovir prophylaxis in transplantation. J Infect Dis 2002;186:116-122
  10. Leone F, Akl A, Giral M, Dantal J, Blancho G, Soulillou JP, Cantarovich D: Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti- viral prophylaxis following renal transplantation. Transpl Int 2010;23:897-906